同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 2025年上半年公司营业收入为60.16亿元，营业收入增长率为12.79%，归属母公司净利润为9.98亿元， 归属母公司净利润增长率为5.03%。 目前公司属于医疗保健行业，主要产品类型为诊断治疗设备，2024年报主营构成为销售医学影像诊断设 备及放射治疗设备:81.99%;提供维修收入:13.16%;其他业务:4.04%;软件收入:0.81%。 同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 联影医疗（688271.SH）2024年营业收入为103.00亿元，营业收入增长率为-9.73 ...

2026 年 02 月 26 日 王睿哲 C0062@capital.com.tw 目标价(元) 153 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- ...

公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- | | 及放射治疗设备 | | | 维保服务 | 9.5% | | 软体业务 | 1.1% | 机构投资 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

Core Insights - The Chinese nuclear technology application industry is transitioning from a "follower" to a "leader" position, with significant advancements in key isotopes and domestic medical equipment [1][2] - The market for radioactive drugs is projected to grow from 9.3 billion yuan in 2025 to 26 billion yuan by 2030, indicating strong growth potential [3][4] Industry Developments - The successful domestic production of Lu-177 isotope marks a significant milestone, enabling targeted therapies for prostate cancer and neuroendocrine tumors, with annual production capacity meeting domestic demand [2][3] - Over 90 types of radiation therapy equipment have been approved for market, with domestic brands accounting for over 70% of the market share, reducing reliance on imports [2][3] Market Potential - The radioactive drug market is expected to grow significantly, with projections indicating a rise from 9.3 billion yuan in 2025 to 26 billion yuan by 2030 [3] - Nuclear technology applications are expanding beyond healthcare into industrial and agricultural sectors, driving modernization and growth [3] Policy and Support - The "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026)" aims for an annual economic output of 400 billion yuan by 2026, supported by legal frameworks and national research facilities [4] - The establishment of a national-level isotope supply base is part of the strategy to enhance supply chain resilience and reduce dependency on single sources [7][8] Challenges and Solutions - The industry faces challenges such as single-point dependency risks for key isotopes and insufficient supply chain elasticity, which could impact stability in nuclear medicine and industrial applications [5][6] - A "Strong Chain Action Plan" has been initiated to address these challenges, focusing on collaborative efforts among state-owned enterprises, research institutions, and private companies to enhance the entire industry chain [7][8] Future Outlook - The nuclear technology application industry is expected to maintain a compound annual growth rate of over 10%, with a target output of 600 billion yuan by the end of the 14th Five-Year Plan [7] - The integration of nuclear technology with AI and new materials is anticipated to create significant new value, potentially exceeding 100 billion yuan during the 14th Five-Year Plan period [8]

Core Insights - The Chinese nuclear technology application industry is transitioning from a "follower" to a "leader" position, particularly in the nuclear medical field, with significant advancements in the supply of key isotopes and domestic market share of radiation therapy equipment [1][2][3] - The market for radioactive drugs is projected to grow from 9.3 billion yuan in 2025 to 26 billion yuan by 2030, indicating strong growth potential in the nuclear medical sector [3] - The "Nuclear Technology Application Industry High-Quality Development Three-Year Action Plan (2024-2026)" aims for the industry to achieve a direct economic output of 400 billion yuan by 2026, with a target of 600 billion yuan by the end of the 14th Five-Year Plan [3][5] Achievements - The successful production of Lu-177 isotope by Qinshan Nuclear Power, which is expected to meet domestic market needs for targeted cancer therapies, marks a significant milestone in self-sufficient isotope supply [1][4] - Over 90 radiation therapy devices have been approved for market use by the National Medical Products Administration, with more than 70% being domestic brands, reducing reliance on imports [2] - The development pipeline for new radioactive drugs has accelerated, with over 200 candidates entering clinical trials, enhancing treatment options for cancer [2] Challenges - The industry faces risks related to single-point dependency on key isotopes and insufficient elasticity in the supply chain, which could jeopardize stability in nuclear medicine and industrial applications [4] - There is a lack of understanding among small and medium enterprises regarding national support policies, leading to difficulties in seizing development opportunities [4] - Issues such as insufficient investment in basic research, weak pilot testing for technology transfer, and imbalanced regional development are hindering overall industry progress [4] Strategic Initiatives - The "Strong Chain Action Plan" was launched to address existing challenges and promote a systematic upgrade of the nuclear technology application industry, involving collaboration among state-owned enterprises, research institutions, and private companies [5][6] - The plan emphasizes a collaborative approach to enhance the entire industry chain, ensuring the stability of domestic isotope supply and fostering innovation through cross-sector integration [6] - The initiative aims to create industrial clusters in key regions to address developmental imbalances and stimulate growth across the industry [6]

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 11.07%, indicating volatility in investor sentiment and market performance [1]. Financial Performance - For the first half of 2025, United Imaging Healthcare reported a revenue of 6.016 billion yuan, representing a year-on-year growth of 12.79%, and a net profit attributable to shareholders of 998 million yuan, reflecting a growth of 5.03% [2]. - Cumulative cash dividends since the company's A-share listing amount to 641 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 23.01% to 16,500, while the average number of circulating shares per person increased by 29.89% to 35,953 shares [2]. - Major shareholders include the Huaxia SSE STAR 50 ETF, which increased its holdings by 3.2169 million shares, and the Hong Kong Central Clearing Limited, which raised its stake by 781,970 shares [3]. Stock Performance Metrics - As of October 22, the stock price was 140.16 yuan per share, with a market capitalization of 115.514 billion yuan. The trading volume was 293 million yuan, with a turnover rate of 0.25% [1]. - The stock has seen a decline of 5.44% over the past five trading days and 8.30% over the last 20 days, while it has increased by 5.07% over the past 60 days [1]. Business Overview - United Imaging Healthcare, established on March 21, 2011, specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and medical digitalization and intelligence solutions. The main revenue sources include medical imaging diagnostic equipment sales (81.29%), maintenance services (13.56%), and software (0.47%) [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices [1].

Summary of United Imaging Conference Call Company Overview - **Company**: United Imaging - **Industry**: Medical Supplies & Devices - **Headquarters**: Shanghai, China - **Ticker**: 688271 CH - **Market Cap**: RMB 125.1 billion [7][32] Key Takeaways Competitive Strategy - United Imaging differentiates itself from global competitors (GE, Philips, Siemens) by maintaining R&D spending above 20% of revenue, enabling faster product launches at lower costs [2][5] - The company focuses on feature-rich products with competitive pricing approximately 15% lower than peers, emphasizing strong service packages over pure price competition [2][5] Growth and Expansion - International sales accounted for nearly 20% of total sales by 1H25, with a target of 50% by 2030, particularly strong growth in Europe with triple-digit growth rates [3][25] - The company is investing in local manufacturing, R&D, and service teams to support overseas expansion, with a new regional HQ in Rotterdam [3][25] Domestic Market Dynamics - China remains a core market, supported by government-backed hospital CAPEX programs with annual incentives ranging from RMB 1 to 1.3 trillion [4][21] - United Imaging holds the 1 domestic market share, with stable gross margins around 50% and potential upside from high-end product mixes [4][23] Financial Projections - Revenue projections for FY 2024A to FY 2027E are as follows: - FY 2024A: RMB 10,300.1 million - FY 2025E: RMB 11,946.6 million - FY 2026E: RMB 15,264.3 million - FY 2027E: RMB 19,119.8 million - Net profit projections for the same period are: - FY 2024A: RMB 1,261.9 million - FY 2025E: RMB 1,720.3 million - FY 2026E: RMB 2,258.4 million - FY 2027E: RMB 2,888.3 million [6][8] Investment Thesis - The company is rated a "Buy" with a price target of RMB 218.00, representing a potential upside of 44% [7][10] - Key growth drivers include localized supply chain efficiency, improved service offerings, and AI-driven competitive advantages in medical imaging [10][19] Risks and Challenges - Risks include policy changes in the medical equipment industry, intense market competition, and challenges in overseas network expansion [33] - The impact of anti-corruption measures has been managed well, allowing the company to maintain its leading market position [23] Sustainability and Social Responsibility - United Imaging aims to reduce carbon emission intensity by 50% by 2035 and extend healthcare access to a broader population [17][18] Market Outlook - The company expects hospital CAPEX in China to drive demand, with government support playing a critical role [20] - The anticipated growth in overseas markets is expected to outpace domestic growth, with a projected 50% year-over-year profit growth for this year [25][26] Conclusion - United Imaging is positioned for significant growth both domestically and internationally, leveraging its competitive advantages in R&D, pricing, and service offerings while navigating potential risks in the market environment [10][19]

Group 1 - The core viewpoint of the news is the performance and market position of United Imaging Healthcare, which saw a stock price increase of 5.08% to 149.89 CNY per share, with a total market capitalization of 1235.33 billion CNY [1] - United Imaging Healthcare was established on March 21, 2011, and went public on August 22, 2022. The company specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital and intelligent medical solutions [1] - The revenue composition of United Imaging Healthcare includes 81.99% from sales of medical imaging diagnostic and radiation therapy equipment, 13.16% from maintenance services, 4.04% from other sources, and 0.81% from software [1] Group 2 - The Qianhai Kaiyuan Fund holds a significant position in United Imaging Healthcare, with its fund, Qianhai Kaiyuan Hong Kong-Shenzhen Leading Selection Mixed A (002443), maintaining 33,400 shares, representing 8.3% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 50.21 million CNY and has achieved a year-to-date return of 1.78%, ranking 7614 out of 8248 in its category, while the one-year return is 14.23%, ranking 6337 out of 8051 [2]

Non-Banking Financials - China Ping An (601318.SH) reported a revenue of 500.1 billion and a net profit of 68 billion for H1 2025, with a year-on-year growth of 1.0% and a decline of 8.8% respectively [2][8] - The operating profit after tax (OPAT) increased by 3.7% to 77.7 billion, while the net assets rose by 1.7% to 944 billion [2][8] - The new business value (NBV) for life insurance grew by 39.8%, and the combined ratio (COR) for property insurance improved by 2.6 percentage points to 95.2% [2][8] Pharmaceuticals - Zai Lab (688266.SH) achieved a total revenue of 376 million, marking a 56.07% increase year-on-year, although it reported a net loss of 73 million [13][14] - The company’s key product, Gika Xini, was approved for market, expected to generate significant revenue [14][15] - The pipeline includes promising candidates like ZG005 and ZG006, which are in various stages of clinical trials and have shown strong efficacy [15][16] Utilities and Environmental Protection - China Nuclear Power (601985.SH) reported a revenue of 40.973 billion, a 9.43% increase, but a net profit of 5.67 billion, down 3.66% year-on-year [18][19] - The company plans to distribute a mid-term dividend of 0.02 per share, reflecting its commitment to shareholder returns [20] - The company has 19 units under construction or approved, with a total capacity of approximately 22GW, ensuring long-term growth [20] Medical Devices - Haitai New Light (688677.SH) reported a revenue of 266 million, a 20.50% increase, and a net profit of 74 million, up 5.52% [22][23] - The company’s medical endoscope revenue reached 207 million, with significant growth in overseas markets [23][24] - The gross margin for the company improved to 65.84%, driven by increased sales and operational efficiency [23][24] Construction and Building Materials - Jianghe Group (601886.SH) reported a revenue of 9.339 billion, a decrease of 5.86%, but a net profit increase of 1.69% to 328 million [30][31] - The company has a high dividend payout ratio of 51.82%, indicating strong investor returns [30][31] - The company is expanding its overseas market presence, with significant growth in orders from international markets [31][32] Transportation - Shentong Express (002468.SZ) achieved a revenue of 25.02 billion, a 16.02% increase, but faced a net profit decline of 3.73% [37][38] - The company’s market share reached 12.9%, with a significant volume of 6.54 billion parcels processed [38][39] - The company is focusing on digital transformation and improving customer service to enhance profitability amid competitive pricing pressures [39][40]